<DOC>
	<DOCNO>NCT00832507</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled , multicenter , dose-ranging study compare efficacy , safety , tolerability cicletanine hydrochloride ( HCl ) placebo subject PAH . Study drug administer alone , background stable PAH therapy . The study consist 3 period : screening period , 12-week placebo-controlled treatment period , long-term , blinded extension period .</brief_summary>
	<brief_title>Study Cicletanine Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>The primary objective study compare change exercise capacity follow treatment cicletanine HCl placebo subject PAH . The secondary objective study : 1 . To compare change clinical measure PAH follow treatment cicletanine HCl placebo subject PAH 2 . To compare safety tolerability cicletanine HCl placebo subject PAH Additionally , long-term safety , tolerability , efficacy cicletanine HCl treatment evaluate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Cicletanine</mesh_term>
	<criteria>Inclusion Criteria Between 16 70 year age Weigh great equal 40 kg Have current diagnosis IPAH , FPAH , PAH primarily due : connective tissue disease , congenital heart defect , drug toxin use , HIV infection Meet follow hemodynamic criterion mean RHC complete prior Screening : mPAP great equal 25 mmHg , PVR great 240 dyne.sec/cm5 , PCWP LVEDP less equal to1 5 mmHg Walk distance least 100 450 screen 6MWT Have WHO functional class II , III , IV symptoms Meet follow pulmonary function test complete 12 week Screening visit : TLC great equal 60 % predict normal &amp; FEV1 great equal 65 % predict normal , FEV1 : FVC ratio great 0.60 Have laboratory result within 90 % low limit normal 1.5 time upper limit normal Receiving treatment approve ERA , PDE5i , and/or parenteral prostanoid must receive therapy great equal 12 week prior Screening Visit must stable dose great equal 4 consecutive week prior Screening Visit . Eligible therapy allow Screening include : a. Monotherapy ERA , PDE5i , parenteral prostanoid approve treatment PAH b . Combination therapy two eligible PAH treatment ( combination ERA , PDE5i , parenteral prostanoid Subject receive diuretic treatment must stable therapy If receive digitalis , CCBs , angiotensin receptor blocker ( ARBs ) , angiotensin convert enzyme ( ACE ) inhibitor , betablocking agent subject must stable therapy If receive HMGCoA reductase inhibitor , subject must stable therapy If diagnosis HIV subject must stable disease status Female subject childbearing potential must negative serum pregnancy test Female subject childbearing potential must agree use 2 reliable method contraception Must agree participate clinical study involve another investigational drug device Must competent understand sign IRB approve ICF Has enrol exercise training program pulmonary rehabilitation must agree enroll exercise training program pulmonary rehabilitation If subject enrol exercise training program pulmonary rehabilitation great 12 week prior Screening Visit must agree maintain current level rehabilitation first 12 week study Must background PAH therapy Screening unless subject access tolerate currently approve PAH medical therapy Exclusion Criteria Subject current PH diagnosis IPAH , FPAH , PAH primarily due : Connective tissue disease , Congenital heart defect , Drug toxin use , HIV infection Subject LVEF less equal 40 % clinically significant ischemic , valvular , constrictive heart disease Subject WHO functional class I symptoms Subject chronically receive ineligible PAH treatment regimen within 4 week prior Screening Visit , specifically : a. inhale iloprost inhaled treprostinil , b. combination treatment three PAH therapy , c.any investigational therapy treatment PAH d.Chronic use consider great 7 consecutive day treatment Subject receive iv inotropes within 2 week prior Screening Visit Subject SBP great equal 150 mmHg less 90mmHg Subject moderate severe liver disease Subject moderate severe renal impairment Subject receive lithium within 2 week prior Screening Visit Subject require intermittent chronic treatment nitrate Subject receive nonantiarrhythmic drug Subject diagnosis long QT syndrome Subject evidence chronic thromboembolic disease Subject obstructive lung disease Subject severe arthritis , musculoskeletal problem , morbid obesity would affect subject 's ability perform complete 6MWT Has history malignancy within past 5 year Subject disease may adversely affect safety subject and/or efficacy study drug severely limit lifespan subject Female subject pregnant breastfeeding Has demonstrate noncompliance previous medical regimen Has recent history abuse alcohol illicit drug Has participate clinical study involve another investigational drug device within 4 week Screening Visit Has know hypersensitivity study drug , metabolite , formulation excipients Receiving oral arginine supplement within 2 week prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>PAH</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>cicletanine</keyword>
	<keyword>cicletanine HCL</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>endothelin receptor antagonist</keyword>
	<keyword>ERA</keyword>
	<keyword>monotherapy</keyword>
	<keyword>combination therapy</keyword>
	<keyword>phosphodiesterase type-5 inhibitor</keyword>
	<keyword>PDE5i</keyword>
	<keyword>parenteral prostanoid</keyword>
	<keyword>PH</keyword>
	<keyword>pulmonary</keyword>
</DOC>